# Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

> **NCT01271998** · PHASE1 · COMPLETED · sponsor: **Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 20 (actual)

## Conditions studied

- Bacterial Infection

## Interventions

- **DRUG:** TR-701 FA

## Key facts

- **NCT ID:** NCT01271998
- **Lead sponsor:** Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-08
- **Primary completion:** 2011-01-03
- **Final completion:** 2011-01-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01271998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01271998, "Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01271998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*